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There is a need for comparative studies to determine which cell types are better candidates to remedy
ischemia. Here, we compared human AC133+ cells and multipotent adult progenitor cells (hMAPC) in a
mouse model reminiscent of critical limb ischemia. hMAPC or hAC133+ cell transplantation induced a
significant improvement in tissue perfusion (measured by microPET) 15 days posttransplantation compared
to controls. This improvement persisted for 30 days in hMAPC-treated but not in hAC133+-injected animals.
While transplantation of hAC133+ cells promoted capillary growth, hMAPC transplantation also induced
collateral expansion, decreased muscle necrosis/fibrosis, and improved muscle regeneration. Incorporation
of differentiated hAC133+ or hMAPC progeny into new vessels was limited; however, a paracrine angio/
arteriogenic effect was demonstrated in animals treated with hMAPC. Accordingly, hMAPC-conditioned,
but not hAC133+-conditioned, media stimulated vascular cell proliferation and prevented myoblast, endothe-
lial, and smooth muscle cell apoptosis in vitro. Our study suggests that although hAC133+ cell and hMAPC
transplantation both contribute to vascular regeneration in ischemic limbs, hMAPC exert a more robust effect
through trophic mechanisms, which translated into collateral and muscle fiber regeneration. This, in turn,
conferred tissue protection and regeneration with longer term functional improvement.
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INTRODUCTION by cell therapy. Unfortunately, clinical trials based on
growth factor delivery have not yielded the expected re-
sults, thereby exposing the need for alternatives (5,13).Peripheral vascular disease (PVD) caused by in-
adequate blood supply to the limbs is a severe health Evidence indicating that adult vasculogenesis—vessel
formation from endothelial progenitor cells (EPC)—is aproblem in the Western world, affecting 3–10% of the
population above the age of 60 (5). Therapeutic revascu- process that contributes to therapeutic neovasculariza-
tion (6) has fueled the interest in the use of this alterna-larization techniques, like laser revascularization, endo-
vascular treatment, or bypass surgery, can in some cases tive paradigm for therapeutic revascularization.
Different (stem) cell populations have been tested inrestore flow and prevent gangrene formation/amputa-
tion. Nevertheless, for many patients, these techniques animals for treatment of hind limb ischemia, like embry-
onic stem cells (ESC) (10), unselected bone marrow mo-are not applicable due to the diffuse nature or the distal
location of the obstructions or coexistence of comorbidi- nonuclear cells (MNC) (17), peritoneal macrophages
(16), adipose tissue-derived stem cells (ADSC) (26),ties. For these no-option patients, alternatives have been
proposed, mainly focused on the induction of tissue re- mesenchymal stem cells (MSC) (18), mature endothelial
cells (EC) (19,35), or EPC (34,35). Overall, results havevascularization by angiogenic gene/protein delivery or
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shown that whereas mature EC transplantation does not prepared from human umbilical cords and muscle biop-
sies as previously described (3,15). Briefly, for SkM iso-induce functional improvement, a variable degree of re-
covery has been demonstrated when MNC or EPC were lation, human muscle biopsies were minced and digested
with trypsin-EDTA (0.5 mg/ml trypsin/0.53 mM EDTA)transplanted. In contrast to earlier reports, more recent
mechanistic studies have revealed that the degree of di- and collagenase (1.5 mg/ml) and isolated cells were
grown in Ham-F12 media (GIBCO-BRL) supplementedrect effects of stem/progenitor cells on revascularization
may be not as robust, and in some cases even negligible with 20% fetal calf serum (FCS) and 1% penicillin/
streptomycin (GIBCO-BRL). HUVEC cells were grown(19). Nevertheless, as a result of the promising preclini-
cal results, at least 40 clinical trials with (stem) cells in F12K medium (ATCC) supplemented with serum
(10%), heparin (0.1 mg/ml), and ECGS (0.03 mg/ml)have already been started in PVD patients (5). Most of
them have evaluated the potential of cord blood cells, and SMC were grown in DMEM high glucose (GIBCO-
BRL) supplemented with 10% serum. Cells were grownperipheral blood-derived MNC, or total bone marrow
(2). A few clinical trials have been performed using en- under normoxic conditions.
riched stem cell populations like CD34+ or AC133+ cells
In Vivo Studiesdemonstrating a clinical benefit [reviewed in (5,13)].
The mean follow-up time in the majority of these studies Surgery. Severe hind limb ischemia was induced un-
was rather short, precluding conclusions on longer term der anesthesia (75 mg/kg ketamine/10 mg/kg xylazine)benefits or possible side effects, the latter as reported in in 6–10-week-old male nude Balbc mice by excision of
one recent study (22).
the left iliac artery as previously described (25). TheTaking together the existing preclinical and clinical
mice were given postoperative analgesia (5 mg/kg keto-data, further studies should primarily focus on defining profen, every day for 3 days). One million cells resus-
the type of stem cell that can exert a greater benefit in pended in 30 µl of PBS, or PBS alone were injected inpatients with critical limb ischemia as well as identify- four equal fractions in the adductor and quadriceps re-ing the mechanism responsible for this effect. In order gion of the left limb, 24 h after surgery. As undifferenti-
to do so, direct comparative studies involving different
ated hMAPC express very low levels of MHC-I and are
cell types are required. Along this line, we recently dem-
thus sensitive to natural killer (NK) cell-mediated clear-
onstrated the superior effect of murine multipotent adult
ance (32), all mice were intraperitoneally injected withprogenitor cells (mMAPC) compared to unfractionated 20 µl of a specific anti-NK antibody (28) (anti-asialo
murine bone marrow cells in a mild hind limb ischemia GM1 antibody; Wako Chemicals) 1–2 h before trans-
model, reminiscent of intermittent claudication (4). In plantation and every 10 days thereafter. Mice were
the current study, we tested the potential of human housed in specific pathogen-free conditions and all pro-MAPC (hMAPC) in a severe model of limb ischemia
cedures were performed according to the guidelines of(resembling critical limb ischemia) and compared it with
the Institutional Animal Care and Use Committee of thehuman AC133+ cells, which have already been used in University of Navarra.
clinical trials. We also compared the main mechanisms
Live Imaging and Assessment of Limb Perfusion.of action of both cell types.
Limb perfusion assessment was performed by microPET
MATERIALS AND METHODS as described by our group (25). Briefly, microPET im-
aging was performed 10 min after 13N-ammonia injec-Cell and Tissue Processing
tion 1, 7, 15, and 30 days after surgery. For quantitativeHuman bone marrow, muscle biopsies, and umbilical
analysis and comparisons among subjects, evaluation ofcord blood (UCB) cells were obtained after informed
perfusion in both hind limbs was carried out as follows:consent from donor or mother according to the guide-
regions of interest (ROIs) were drawn on coronal 1-mm-lines from the Committee on the Use of Human Subjects
thick microPET images over the hind limbs, and activityin Research from the Clı´nica Universitaria, Pamplona.
concentration per area unit calculated as a measurementUCB mononuclear cells were separated by Ficoll Hy-
of perfusion. The ratio between left (ischemic) and rightpaque centrifugation (specific gravity, 1077; Sigma, St.
(nonischemic) hind limbs was used in all cases for com-Louis, MO, USA) and hAC133+ cells were selected us-
parisons and obtained data were exported to the PMODing micromagnetic beads (Miltenyi Biotec, Germany)
software package for quantification.with autoMACS columns (Miltenyi Biotec) as described
(3). More than 90% cell purity was obtained after col-
Histological Analysisumn selection. hMAPC were obtained according to pub-
lished protocols (3,4). Primary human umbilical vein en- At sacrifice (day 15 and day 30), mice were anesthe-
tized with 60 mg/kg Nembutal and perfused with Tris-dothelial cells (HUVEC), umbilical arterial smooth
muscle cells (SMC), and skeletal myoblasts (SkM) were buffered saline (TBS)-adenosine and followed by zinc-
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paraformaldehyde. Following dissection, muscles were were seeded in 96-well plates at a density of 103 cells/
cm2 (HUVEC) or 5,000 cells/cm2 (SMC and SkM) andpostfixed 24 h and divided in two equal pieces to be
processed for paraffin embedding. H&E and Sirius red cultured under hypoxic conditions (1% O2) in the pres-
ence of CM, NCM, or in normal cell culture conditionsstainings were performed as described (3). Those areas
with presence of fat cells replacing muscle fibers, in- (CCM) (20% O2 and cell culture media) during 24 h for
HUVEC and 72 h for SMC and SkM cells. For thisflammatory infiltrates, or “ghost” cells (muscle cells
without nucleus) were considered necrotic areas. For im- assay, no serum was added to the CM. The degree of
cell apoptosis was measured by an ELISA kit that quan-munofluorescence and immunohistochemistry, antibod-
ies against α-smooth muscle actin (α-SMC, unconju- tifies the presence of oligonucleosomal fragments
(Roche Applied Science, Barcelona, Spain). The apopto-gated, DAKO; or Cy3 or FITC conjugated, Sigma),
human CD31 (DAKO or Pharmingen), UEA lectin (bio- sis control corresponds to cells cultured under hypoxia
and NCM. Under this condition apoptosis was clearlytin, TRITC, or FITC, conjugated; Sigma), mouse BS-I
lectin (Sigma), human vimentin (DAKO), and desmin detected and considered 100%. The rest of the samples
were referred to that value, in order to determine the(DAKO) were used as primary antibodies. Secondary
antibodies coupled to FITC or peroxidase enzyme were degree of “protection” conferred by the conditioned me-
dia. Four independent experiments were performed onpurchased from Molecular Probes. For quantification,
analyses were done on cross sections with regular inter- cells seeded in quadruplicate.
vals spanning 2 mm. When technically feasible, entire
RNA Isolation, qRT-PCR, and ELISAcross sections were evaluated on lower power field im-
Total RNA from hAC133+ and hMAPC was ex-ages, or when higher magnification was required several
tracted using the RNAeasy minikit (Qiagen). mRNA(usually 3–4 per section) randomly chosen higher power
was reverse transcribed using Superscript III Reversefields covering a large part of each cross section were
Transcriptase (Invitrogen) and cDNA underwent 40 cy-analyzed. Pictures for morphometric analysis were taken
cles of amplification (ABI PRISM 7700, Perking Elmer/using a Zeiss Axio Imager connected to an Axiocam
Applied Biosystems). SYBR Green Universal Mix PCRMRc5 camera (Zeiss, Zaventem, Belgium) and analysis
reaction buffer (Applied Biosystems) was used for quan-was performed using Image J, KS300 (Leica, Brussels,
tification, normalizing data using GAPDH as housekeep-Belgium).
ing gene. Cytokine levels present in hMAPC or hAC133+
conditioned and nonconditioned medias were quantifiedIn Vitro Proliferation and Apoptosis Assays
by ELISA. For human VEGF, bFGF, and Ang-2, ELISA
Proliferation. hMAPC were cultured in MAPC me- kits were purchased from R&D Systems and ELISA
dium (3) with 2% FCS but without cytokines at a den- procedures were followed according to the manufactur-
sity of 17,500 cells/cm2, and hAC133+ cells were cul- er’s instructions.
tured in DMEM high glucose supplemented with 2%
Statistical AnalysisFCS at a density of 105/cm2. Conditioned media (CM)
were collected after 48 h. Corresponding media incu- All data are expressed as mean ± SEM or median
bated without cells for 48 h served as controls [noncon- (Q1; Q3). Comparisons for repeated measurements were
ditioned media (NCM)]. Early passages of HUVEC, performed by ANOVA or Kruskal-Wallis tests. Shapiro-
SMC, or SkM were seeded in 24-well plates at a cell Wilk test was used to verify that the data had a Gaussian
density of 1,250 cells/cm2 (HUVEC and SkM) or 625 distribution, which justifies the use of a parametric test.
cells/cm2 (SMC), respectively, and cultured in the pres- Tukey, Tukey’s b, and Tamhane’s T2 post hoc tests
ence of hMAPC or hAC133+ CM or NCM. In order to were performed after ANOVA and U-Mann-Whitney 1:
obtain the same cell concentration as hMAPC, hAC133+ 1 with signification correction by Bonferroni’s method
CM was previously diluted and all media were supple- for the nonparametric tests. Statistical analysis was per-
mented with extra serum to reach a 6% FCS concen- formed with Instat 3.0 software and differences were
tration. After 72 h, the number of viable cells was considered statistically significant when p < 0.05.
quantified by a luminiscent cell viability assay (Cell
RESULTSTiter-GloTM, Promega, USA) following the manufactur-
er’s protocol. Four independent experiments were per- hMAPC Have a More Durable Effect on Limb
formed and every cell type grown in CM or NCM was Reperfusion Than hAC133+ Cells
seeded in quadruplicate. The revascularization potential of hAC133+ cells and
hMAPC was compared in a severe ischemia model in-Apoptosis. CM from hMAPC and hAC133+ were
collected as described before, after 12-h culture in non- duced by iliac artery excision. After 24 h, such injury
caused a dramatic decrease in blood perfusion (70%)serum-containing media. Endothelial and skeletal cells
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in the ischemic limb (Fig. 1). By day 15, PBS-injected Unlike hAC133+ Cells, hMAPC Significantly Improve
Muscle Viability and Regenerationanimals presented a spontaneous recovery in blood flow
(54 ± 3% at 15 days vs. 23 ± 3% at 24 h). In comparison In a next series of analyses, we determined whether
with this group, a significantly greater recovery was de- there was a correlation between revascularization and
tected in the animals transplanted either with hAC133+ the degree of tissue damage or regeneration, by analyz-
cells or hMAPC (PBS: 54 ± 3%; hAC133+: 74 ± 7%, p < ing muscle necrosis, fibrosis, and regeneration 30 days
0.05; hMAPC: 64 ± 4%, p < 0.05). Importantly, 30 days posttransplantation. Necrosis and fibrosis were signifi-
posttransplantation, while animals treated with hMAPC cantly lower in the hMAPC-treated but not in hAC133+-
presented a significantly higher blood flow, perfusion treated animals, compared to PBS [% necrosis: 31 ± 5
recovery was no longer significantly different from con- in PBS; 27 ± 5 in hAC133+, P = NS and 12 ± 5 in
trols in the animals treated with hAC133+ (PBS: 66 ± hMAPC, p < 0.05; hMAPC vs. hAC133+, p < 0.05 (Fig.
3%; hAC133+ cells: 73 ± 5%, p = NS; hMAPC: 77 ± 3A–D); % fibrosis: 15 ± 2 in PBS; 12 ± 3 in hAC133+,
3%, p < 0.05) (Fig. 1), suggesting that hMAPC exerted P = NS and 8 ± 2 in hMAPC, p < 0.05; hMAPC vs.
a more robust and prolonged effect on reperfusion than hAC133+, NS (Fig. 3E–H)]. Moreover, also by day 15,
hAC133+ cells. necrosis and fibrosis were significantly lower in the
hMAPC-treated animals than in the hAC133+-treatedhMAPC and hAC133+ Cells Have a Differential Effect
ones (data not shown). Finally, we evaluated the degree
on Blood Vessel Growth
of muscle regeneration (myogenesis), defined by the
We first examined whether the different effects on presence of fibers with strong positivity for desmin (14).
reperfusion could be explained by histological assess- Unlike hAC133+ cell-injected muscles, at day 30,
ment of blood vessel growth. In the ischemic adductor hMAPC-treated muscles showed a statistically signifi-
region, vascular expansion occurs by a combination of cant higher expression of this marker compared with
three mechanisms: vasculogenesis (vascular precursor nontreated limbs [% desmin area: 1.15 ± 0.15 in PBS;
incorporation into growing vessels), angiogenesis (capil- 1.51 ± 0.13 in hAC133+, p = NS; 1.71 ± 0.17 in hMAPC,
lary growth), and adaptive arteriogenesis (collateral p < 0.05; hMAPC vs. hAC133+, NS) (Fig. 3I–L), a dif-
expansion). First, direct contribution of hMAPC or ference that was already detected at day 15 (data not
hAC133+ vascular progeny was studied at 30 days after shown). These results suggest a unique capacity of
surgery. As we have previously reported, direct contri- hMAPC to contribute to muscle regeneration compared
bution of hMAPC to both EC (human specific CD31 to hAC133+ cells.
and UEA positive) and SMC layers (human vimentin
hMAPC Secrete Factors That Protect Againstand α-actin double positive) of the newly formed vessels
Apoptosis and Stimulate Proliferationwas confirmed in the adductor region. However, this
contribution was limited (Fig. 2A–C) (4). On the other Because direct contribution to vessels was limited,
we hypothesized that the beneficial effects on revascu-hand, hAC133+ cells also contributed to the EC lineage,
although they did not differentiate into SMC (Fig. 2D– larization and muscle regeneration were due to trophic
effects on endogenous cells. Therefore, we measuredF). The remaining hAC133+ cell fraction at 30 days was
too low to allow for reliable quantification. Thus, for growth factor secretion and performed experiments with
CM on vascular and muscular cells. Quantification byboth cell types, vascular incorporation was low, which
makes it unlikely that vasculogenesis was the main re- qRT-PCR showed a higher expression of proangiogenic
and arteriogenic factors (VEGF165, bFGF, and PlGF) invascularization mechanism.
Next, we quantified the effect of cell transplantation hMAPC versus hAC133+ cells (hMAPC vs. hAC133+
cells: % expression vs. universal RNA: VEGF165: 236 ±on capillary growth and collateral expansion. Both cell
types had a significant effect on both parameters; how- 144 vs. 8.4 ± 0.4; PlGF: 1828 ± 2407 vs. 10 ± 5; bFGF:
452 ± 106 vs. 12 ± 17). Protein secretion, determined byever, they had a differential effect on these processes.
While hAC133+ cells mainly affected capillary growth ELISA, confirmed the higher secretion of VEGF165,
bFGF, and PlGF by hMAPC (hMAPC vs. hAC133+(small CD31+ vessels/mm2: 290 ± 36 in PBS; 759 ± 96
in hAC133+, p < 0.01 and 493 ± 45 in hMAPC, p < cells: pg/105 cells: VEGF165: 8066 ± 636 vs. undetect-
able; bFGF: 20 ± 3 vs. undetectable; PlGF: 11 ± 5 vs.0.01; hMAPC vs. hAC133+, p < 0.05) (Fig. 2G–J), the
effect of hMAPC on collateral expansion was much undetectable).
To determine whether the release of growth factorsmore apparent (α-actin-coated vessel area %: 0.32 ± 0.10
in PBS; 0.59 ± 0.10 in hAC133+, p < 0.05 and 0.72 ± by the transplanted cells could be responsible for the
observed beneficial effect on vascular/muscular regener-0.14 in hMAPC, p < 0.05; hMAPC vs. hAC133+, p <
0.05) (Fig. 2K–N). ation in vivo, we analyzed the potential of hAC133+ cell-
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Figure 1. hMAPC have a more durable effect on limb reperfusion than hAC133+ cells. (A) Repre-
sentative 13N-ammonia PET images taken 1, 7, 15, and 30 days after ischemia and transplantation
of PBS, hAC133+ cells, or hMAPC are shown. Arrowheads indicate the ischemic limb. (B) 13N-
Ammonia uptake in animals treated with PBS (white bars), hAC133+ cells (gray bars), and hMAPC
(black bars) are shown at the different time points as the mean% ± SEM blood perfusion relative
to the nonischemic limbs (N = 7–10 mice/group). *p < 0.05.
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Figure 2. hMAPC and hAC133+ cells have a differential effect on blood vessel growth. (A–F) Analysis of direct contribution
(vasculogenesis) by immunofluorescence-stained cross sections of hMAPC-transplanted (A–C) or hAC133+-transplanted (D–F)
adductors for UEA lectin, only recognizing human EC (red in A, green in D), human-specific CD31 (green in B, E) indicating the
endothelial identity of the transplanted cells (arrowheads), and double staining for human vimentin (recognizing human mesodermal
cells like EC and smooth muscle cells) (green in C, F) and smooth muscle α-actin (recognize both human and mouse smooth
muscle cells) (red in C, F) showing colocalization in hMAPC but not in hAC133+ cells. (G–J) Analysis of endogenous angiogenesis
status. Representative pictures of capillary density (revealed by mouse-specific CD31 in green) in PBS (G), hAC133+ (H), or
hMAPC-treated (I) quadriceps muscles and corresponding quantification (J; data expressed as number of capillaries/muscle area in
mm2; mean ± SEM). (K–N) Representative pictures of collaterals (arteriogenesis) [revealed by (mouse and human) smooth muscle
α-actin in red] in PBS (K), hAC133+ (L), or hMAPC-treated (M) quadriceps muscles and corresponding quantification (N; data
expressed as fractional area in % ± SEM; N = 4–6 mice per group). DAPI was used for nuclear staining in (A–I, K–M). *p < 0.05
and **p < 0.01 versus PBS. Scale bars: 50 µm (A–F) and 400 µm (G–I, K–M).
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or hMAPC-derived CM to induce proliferation and/or to hMAPC CM with a trend towards statistical significance
(data not shown); however, unlike hAC133+ CM,inhibit apoptosis of vascular/muscular cells. Culture of
EC and SMC in the presence of hMAPC but not hMAPC CM exerted a potent antiapoptotic effect on
SkM when these were exposed to hypoxia or serum dep-hAC133+ CM induced a significant increase in their pro-
liferation rate in comparison with the NCM (EC prolif- rivation [% SkM apoptosis vs. NCM (100%): 3 ± 3 for
CCM, p < 0.01, 97 ± 16 for hAC133+ CM, p = NS, anderation relative to NCM: 1.0 ± 0.2-fold for hAC133+
CM, p = NS and 6.5 ± 0.8-fold for hMAPC-CM, p < 20 ± 8 for hMAPC CM, p < 0.01] (Fig. 4C). Thus,
hMAPC, but not hAC133+ cells, had a beneficial effect0.05; SMC proliferation relative to NCM: 0.9 ± 0.1-fold
for hAC133+ CM, p = NS and 1.4 ± 0.2-fold for on vascular/muscular cell proliferation and/or survival
through paracrine effects.hMAPC-CM, p < 0.05) (Fig. 4A, B. In addition, while
hMAPC-CM almost completely abrogated the apoptosis
DISCUSSIONinduced by hypoxia (1% O2) and serum deprivation in
the EC and SMC, no significant protection was observed The already high incidence of PVD will further in-
crease due to a growing number of patients that carrywhen cells were cultured in the presence of hAC133+
CM [% EC apoptosis vs. NCM (100%): 7 ± 3 for CCM risk factors (e.g., diabetes, hypertension) predisposing
them for developing PVD. At the same time, for many(normoxia and 10% FCS), p < 0.01, 84 ± 8 for hAC133+
CM, p = NS and 35 ± 12 for hMAPC-CM, p < 0.05; % of these patients these risk factors may limit the thera-
peutic options for revascularization. The demonstrationSMC apoptosis vs. NCM (100%): 18 ± 1 for CCM, p <
0.01, 87 ± 5 for hAC133+ CM, p = NS and 21 ± 10 for of postnatal vasculogenesis (6) fueled a boost in preclin-
ical studies as well as a rapid clinical translation of thishMAPC CM, p < 0.05] (Fig. 4C). Finally, the effect of
CM on SkM proliferation was moderate in the case of concept. However, many issues need to be resolved be-
Figure 3. Unlike hAC133+ cells, hMAPC significantly improve muscle viability and regeneration. (A–D) Representative pictures
of necrosis (defined by dead muscle cells, fat, and inflammatory clusters on H&E) in PBS (A), hAC133+ (B), or hMAPC-treated
(C) quadriceps muscles and corresponding quantification (D); data expressed as fractional area in % ± SEM (N = 4–6 mice per
group). (E–H) Representative pictures of fibrosis (revealed by Sirius red staining) in PBS (E), hAC133+ (F), or hMAPC-treated
(G) quadriceps muscles and corresponding quantification (H); data expressed as fractional area in % ± SEM (N = 4–6 mice per
group). (I–L) Representative pictures of myogenesis (revealed by desmin staining) in PBS (I), hAC133+ (J), or hMAPC-treated (K)
quadriceps muscles and corresponding quantification (L; data expressed as fractional area in % ± SEM; N = 4–6 mice per group).
*p < 0.05 versus PBS. Scale bars: 200 µm (E–G) and 400 µm (A–C, I–K).
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Figure 4. hMAPC secrete factors that protect against apoptosis and stimulate proliferation. (A, B) HUVEC and SMC were cultured
in NCM, hAC133+ CM, or hMAPC CM for 72 h. Cell proliferation is shown as fold increase in comparison with proliferation in
NCM. The mean ± SEM of four different experiments in quadruplicate is shown as well as representative pictures showing the cell
density differences after 72 h. *p < 0.05. (C) Apoptosis of HUVEC, SMC, and skeletal myoblasts (SkM) induced by hypoxia and
serum deprivation was measured by ELISA after 24 h (HUVEC) or 72 h (SMC and SkM) in culture in the presence of NCM,
CCM (cell culture media and normoxia), hAC133+ CM, or hMAPC-CM. Values are expressed as percentage of apoptosis relative
to the control group (cells in hypoxic conditions cultured with NCM) where apoptosis was considered 100%. The mean ± SEM of
four different experiments in quadruplicate is shown. *p < 0.05; **p < 0.01.
fore cell transplantation becomes routine practice for like hAC133+ cells, hMAPC stimulated muscle regener-
ation to a statistically significant extent in this severePVD treatment. In this context, we performed a recent
study in which we compared murine unfractionated bone ischemic setting.
We chose to compare hMAPC with hAC133+ cellsmarrow cells with mMAPC in a model reminiscent of
intermittent claudication, a milder PVD form (4). The because the latter are already used in clinical PVD trials
(8,9,20). AC133 (or prominin-1) is a surface antigen ex-current study was intended to further extend these stud-
ies in order to increase our understanding of the role of pressed on precursors with hematopoietic, neuronal, en-
dothelial, or myogenic potential (30). Our study is notstem cells in ischemic disease: by comparing two popu-
lations of human-derived cells; by following up the ef- the first to evaluate these cells in a preclinical PVD
model; however, in most of the studies, their potentialfects of transplantation for longer term; by testing the
cells in a severe limb ischemia model, reminiscent of was not compared to that of other stem cell sources and
the study settings were also different (7,27,31). Unlikecritical limb ischemia (which is the main target for cell
therapy); and by performing mechanistic studies to get in the majority of these studies, we used a severe model
(by more proximal ligation/excision combined with aninsight into the way these cells may have beneficial ef-
fects. We found that hMAPC had a more durable effect immune-deficient and low collateral reserve BalbC ge-
netic background) and followed the effects on bloodon revascularization than hAC133+ cells. In addition, un-
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flow recovery beyond 3 weeks of transplantation. While was observed even macroscopically in hMAPC-treated
limbs, suggesting a more durable effect of this cell pop-hMAPC had a sustained and progressive effect on perfu-
sion recovery, the initial benefit of hAC133+ cell trans- ulation in comparison with AC133+ cells. Additional
studies in large animal models will contribute valuableplantation was lost at 1 month, with a regression of the
capillary vessels from day 15 to day 30. Interestingly, the information for future application of hMAPC in patients.
The direct contribution of hAC133+ or hMAPC tomost recent clinical study with the latter cells also showed
that the initially observed functional improvement was no muscle fibers has not been analyzed in the current study.
However, we have previously demonstrated a limitedlonger significant after a 1-year follow-up (8).
Several reasons may explain the temporary nature of contribution of mMAPC to skeletal muscle in a similar
hind limb model, even though mostly due to fusion pro-the hAC133+ cell treatment effect. One may be the lim-
ited engraftment of the cells in the inflammatory ische- cesses (4). Although we cannot rule out a direct muscle
(trans)differentiation of hMAPC or even hAC133+ cells,mic environment. This may be overcome by delivering
the cells on a matrix scaffold, as recently demonstrated the limited engraftment suggests that muscle regenera-
tion was mainly derived from stimulation of endogenousin ischemic rat limbs (31). As for the clinical studies,
another problem relates to the functional deficit of EPC cells induced by factors secreted from hMAPC.
The existence of stem/progenitor cells with broad dif-derived from patients with risk factors (12,23). Recent
studies have revealed that these functionally deficient ferentiation potential, such as ESC, and more recently
induced pluripotency cells has raised many hopes forcells can be “reeducated” by pretreatment with (angio-
genic) growth factors (33). In the current study we pro- regenerative approaches, because one cell type would be
sufficient to supply cells for many different damagedpose another reason for the temporal benefit of hAC133+
cells compared to the sustained effect of hMAPC (i.e., tissue types. However, in the last 5 years this paradigm
has been shifting, because many studies have nowa differential mechanism of revascularization). While
hAC133+ mainly affected capillary growth, hMAPC had shown that the main benefit of stem cell transplantation
may rather result from their trophic activity. Also in thea significant effect on collateral growth. The latter is
responsible for delivering the bulk flow and hence may context of ischemia, the potential of stem cells to confer
functional and perfusional improvement by the produc-represent a more crucial requirement for long-term re-
vascularization of the ischemic tissue. tion of cytokines is by no means a new concept (18,19).
In our previous study (4), we pointed out that alsoThe importance of muscle regeneration is often not
considered when evaluating cell therapy studies for limb mMAPC have a beneficial effect on vessel and muscle
regeneration mainly by secreting growth factors such asischemia. However, from our earlier comparative stud-
ies, it was apparent that, even in case of a milder form of VEGF and IGF-1. Here, we show that also hMAPC se-
crete significant amounts of VEGF165, PlGF, and bFGF,ischemia, cells with a combined vascular and muscular
regeneration effect, such as undifferentiated mMAPC, while hAC133+ cells did not produce these factors at
levels that were detectable by our ELISA assays. Ac-had a more durable effect on limb functional recovery
compared to cells with a restricted vascular regenerative cordingly, CM from hMAPC but not hAC133+ cells
stimulated EC, SMC, and SkM proliferation and/or sur-effect, such as vascular predifferentiated mMAPC (4).
Most likely, muscle regenerative effects are even more vival. Our failure to detect VEGF or other cytokines in
hAC133+ CM may appear in conflict with a recentdesirable in more severe forms of ischemia, such as in
the model used in the current study. While this has not study; however, they used cells from a different source
(fetal aorta versus cord blood in our study) (7).been shown in a limb ischemia model, hAC133+ cells
have been recently reported to contribute to skeletal Patients with myocardial infarction (MI) can also
benefit from treatment with endothelial progenitor cells.muscle regeneration in a model of muscle injury (29).
Here, there was a trend towards stimulation of muscle In fact, functional improvement has been shown after
MAPC or AC133 treatment (1,11,21,24), although un-regeneration (estimated by the appearance of desmin-
positive regenerating fibers) following hAC133+ cell fortunately, a direct comparison between the different
cell types has not been performed. In accordance withtreatment; however, this did not reach statistical signifi-
cance. hMAPC, on the other hand, did stimulate myo- our results in the limb ischemia model, low/absent en-
graftment and differentiation potential of both cell typesgenesis to a significant extent, confirming our previous
observations (4). Therefore, despite higher perfusion ca- have been demonstrated, suggesting that paracrine
mechanisms are responsible of the benefit observed. Inpacity and greater capillary density induced by day 15
in the AC133+-treated tissues, no significant effect on fact, we have shown that secretion of angio/arteriogenic
factors by MAPC are associated with revascularizationmuscle necrosis was observed, suggesting that the indi-
rect effect exerted by the hMAPC in muscle regenera- of the ischemic tissue (24).
In summary, our study demonstrates that locally in-tion was critical for limb recovery. Muscle regeneration
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in patients with critical limb ischemia. Bone Marrowjected hMAPC but not hAC133+ cells have a long-term
Transplant. 45:111–116; 2010.effect on limb revascularization and, in addition, con- 9. Canizo, M. C.; Lozano, F.; Gonzalez-Porras, J. R.; Barros,
tribute to muscle regeneration. We believe that these re- M.; Lopez-Holgado, N.; Briz, E.; Sanchez-Guijo, F. M.
sults set the stage for future clinical trials with hMAPC Peripheral endothelial progenitor cells (CD133 +) for ther-
apeutic vasculogenesis in a patient with critical limb is-in patients with critical limb ischemia.
chemia. One year follow-up. Cytotherapy 9:99–102; 2007.
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